NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics Inc. (OTC: GALT) today announced that John Mauldin, a member of its Board of Directors, plans to purchase Company stock on a periodic basis by entering into a 10b5-1 plan, and on October 1st, featured the Company in his e-newsletter, “Thoughts from the Frontline”, a highly acclaimed newsletter that is primarily focused on private money management, financial services, and investments. Each week, more than one million readers turn to Mauldin for his penetrating view on Wall Street, global markets, and economic history. Mauldin’s article can be read at http://howestreet.com/2011/10/tough-choices-big-opportunities/. SEC Rule 10b5-1 allows officers, directors and other insiders of publicly traded companies to transact in their company shares at all times, not just during open trading windows.
